Skip to content

Clinical Trial Comparing Negative Pressure Wound Therapy and Standard Dry Dressings

Monocentric Randomized Clinical Trial Comparing Negative Pressure Wound Therapy (PREVENA™) and Standard Dry Dressings on Oozing of Closed Incision After Revision Total Hip and Knee Arthroplasty Surgery or Lower Extremity Amputation Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04520841
Acronym
BERLYTZ
Enrollment
200
Registered
2020-08-20
Start date
2020-06-01
Completion date
2024-06-01
Last updated
2022-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amputation, Arthroplasty Complications, Prosthesis-Related Infections

Keywords

Prevena, Negative Pressure Wound Therapy, Revision Arthroplasty, Lower Extremity Amputation Surgery

Brief summary

Negative pressure dressings are currently widely used in wound management. Their use is gradually being extended to surgical scars. However, studies demonstrating a clear benefit are rare, particularly in terms of postoperative discharge, the need for surgical revision due to prolonged oozing and cost. The aim of this study is to evaluate the benefit of such a device in post-operative revision prosthesis surgery (hip and knee), as well as lower limb amputations.

Interventions

DEVICEPrevena TM

A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.

DEVICEDry dressing

A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery

Sponsors

University of Lausanne Hospitals
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Signed informed consent * Age ≥ 18 years old * Planned Surgery : 1. revision of a hip or knee prosthesis, in 1 or 2 stages, at explantation and/or reimplantation, where 2. elective amputation of a lower limb (transmetatarsal, trans-tibial (Burgess) or trans-femoral (Gritti-Stokes) level (nb: patients for whom amputation of both lower limbs is planned will be excluded)

Exclusion criteria

* Known allergy to dry dressings * Patient already included in another clinical trial * Inability to discern and/or inability to follow study procedures * Known allergy to silver or another component of the system Prevena™ * Amputation for tumor pathology

Design outcomes

Primary

MeasureTime frameDescription
Discharge after 7 daysDay 7- Day 8Presence of discharge at 7 days postoperatively (Day 7) Condition of the dry dressing applied on Day 7 and evaluated at least 24 hours after application (Day 8)

Secondary

MeasureTime frameDescription
Revision surgeryDay 0 - Day 14Occurrence of revision surgery due to persistent discharge from the day of the operation (Day 0) until discharge from hospital (or max Day 14)
HospitalisationDay 0 - Day 14Duration of hospitalisation from Day 0 to end of hospitalisation (in days)
ComplicationsDay 0 - Day 14Occurrence of post-operative complications from Day 0 to hospital discharge (or max Day 14)
CostsDay 0 - Day 7Dressing repair costs (sum of the price of all dressings and materials needed for dressing repair) from Day 0 to Day 7 (in Swiss francs)
AE & ADEDay 0 - Day 14Occurrence, intensity, severity, causal link with the medical device and the procedure, and characteristics of the adverse events (AEs) considered to be at least possibly related to the medical device or the procedure (= adverse events, ADEs), occurring from the day of the operation (Day 0) until discharge from hospital (or max Day 14).
Patient satisfactionDay 7Reported patient satisfaction based on the responses obtained from the Patient Evaluation Form questionnaire completed by the patient. A numeric pain scale is included: the patient rates his pain on a scale of 0 to 10 when the last dry dressing (Opsite TM) is changed or when Prevena system (TM) is removed. Zero means no pain, and 10 means the worst possible pain.Participant will complete the questionnaire on Day 7.

Countries

Switzerland

Contacts

Primary ContactSylvain Steinmetz, MD
sylvain.steinmetz@chuv.ch+41 (0)21 314 27 89
Backup ContactDiane Wernly, MD
wernly.diane@gmail.com+41 (0)76 581 49 73

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026